melior melior discovery melior pharmaceuticals preclinical services pre-clinical services in vivo pharmacology in vivo efficacy efficacy models pharmacokinetics indications discovery specialized animal models bioanalytical services theratrace exton pennsylvania cro contract research drug discovery drug development metabolic disease alzheimer’s alzheimers diabetes reprofiling
Melior Discovery
home
Our Services
High Throughput In Vivo Pharmacology:
Discovery Services:
Our Technology
 

“I have been working with Melior on a number of projects over the course of a few years now.  They have been a great partner throughout this time.  The scientists whom I have worked with have been great problem-solvers and were customer focused.”

– Jay Lichter,
Avalon Ventures

Click here to download the Melior Brochure        

Click here to download the Melior Models list           

theraTRACE

Melior Pharmaceuticals

 

melior melior melior discovery melior pharmaceuticals preclinical services pre-clinical services in vivo pharmacology in vivo efficacy efficacy models pharmacokinetics indications discovery specialized animal models bioanalytical services theratrace exton pennsylvania cro contract research drug discovery drug development metabolic disease alzheimer’s alzheimers diabetes reprofiling

Our Services specialized animal models

 
   


Melior Announces the Availability of an Exclusive Model for Alzheimer’s DiseaseMelior Announces the Availability of an Exclusive Model for Alzheimer’s Disease

Available murine models of Alzheimer’s disease rely solely upon the super normal expression of amyloid precursor protein (APP) which is not predictive of the human condition. In addition, available models exhibit exponential plaque deposition kinetics which may confound efforts to identify drug candidate efficacy. Melior’s proprietary huAβ mouse model is capable of reliably and predictably assessing plaque deposition relevant to the progression of human Alzheimer’s disease. Melior’s neuroTRACEdg platform provides the addition of Melior Discovery’s complementary behavioral models, so that improvement of cognitive deficits in Alzheimer’s disease can be effectively evaluated.

Melior's theraTRACE® discovery platform includes over 35 standardized and validated models relevant to the following indications/therapeutic areas:

  • Neurodegenerative Diseases
    • Epilepsy
    • Multiple Sclerosis
    • Alzheimer's disease*
    • Parkinson's disease
  • Psychiatry
    • Anxiety
    • Addiction
    • Depression
  • General Neurology
    • Irwin Evaluations
    • Locomotor Activity
    • Circadian Rhythm
    • Thermoregulation
  • Pain
    • Mechanical
    • Thermal
    • Chemical
    • Visceral
  • Inflammation
    • Arthritis
    • Asthma
    • Sepsis
  • Neuroinflammation
    • Multiple Sclerosis
  • Cardiovascular
    • Hypertension
    • Thrombosis
    • Small Animal Telemetry
  • Metabolic Disease
    • Diabetes (type II)
    • Metabolic Syndrome
    • Obesity
  • Gastrointestinal
    • Irritable Bowel Syndrome
    • Morphine-induced constipation
  • Immunology
    • Allergic reaction
    • Monocyte infiltration
  • Urology
    • Overactive Bladder

* Amyloid Plaque Deposition - Exclusive Model

Back to top of page